PielPub Date : 2024-06-01DOI: 10.1016/j.piel.2023.11.012
Victor Meza Viteri , Antonia Mori , Andrés Figueroa
{"title":"Granuloma facial tratado con corticoides intralesionales y terapia láser","authors":"Victor Meza Viteri , Antonia Mori , Andrés Figueroa","doi":"10.1016/j.piel.2023.11.012","DOIUrl":"10.1016/j.piel.2023.11.012","url":null,"abstract":"","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 6","pages":"Pages 371-374"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140789661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PielPub Date : 2024-06-01DOI: 10.1016/j.piel.2024.03.006
Sofia Gómez-Martínez , Daniel Morgado-Carrasco
{"title":"Aprobación de biosimilares de ustekinumab: ¿un cambio en la primera línea del tratamiento biológico de la psoriasis?","authors":"Sofia Gómez-Martínez , Daniel Morgado-Carrasco","doi":"10.1016/j.piel.2024.03.006","DOIUrl":"https://doi.org/10.1016/j.piel.2024.03.006","url":null,"abstract":"","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 6","pages":"Pages 315-316"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141286337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PielPub Date : 2024-06-01DOI: 10.1016/j.piel.2024.02.001
Miguel Mansilla-Polo , Begoña Escutia-Muñoz , David Hervás-Marín , Blanca de Unamuno-Bustos , Carlos Abril-Pérez , Rafael Botella-Estrada
{"title":"Efectividad y seguridad de los fármacos biológicos y las moléculas pequeñas en la hidradenitis supurativa: experiencia en un centro terciario y propuesta de un algoritmo terapéutico","authors":"Miguel Mansilla-Polo , Begoña Escutia-Muñoz , David Hervás-Marín , Blanca de Unamuno-Bustos , Carlos Abril-Pérez , Rafael Botella-Estrada","doi":"10.1016/j.piel.2024.02.001","DOIUrl":"10.1016/j.piel.2024.02.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Hidradenitis suppurativa is an occasionally devastating inflammatory skin disease. Currently, adalimumab is the only approved biological or small molecule medication for its treatment.</p></div><div><h3>Objectives</h3><p>To evaluate the efficacy and safety of biological or small molecule drugs other than adalimumab, with the ultimate goal of proposing a standardized therapeutic algorithm.</p></div><div><h3>Methods</h3><p>A retrospective study was conducted with all biological or small molecule drugs other than adalimumab in a tertiary hospital. Objective and subjective measurements were recorded through an analysis before (prior to the introduction of the medication) vs. after (withdrawal of the medication or end of the study period).</p></div><div><h3>Results</h3><p>Better response rates than adalimumab were found in most of the objective response items (Hurley, IHS4, HSSI, modified Sartorius) and subjective response items (DLQI, pain, itching, sexual relationships, therapeutic satisfaction) with infliximab leading, followed by ustekinumab, brodalumab, and secukinumab.</p></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 6","pages":"Pages 317-330"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PielPub Date : 2024-06-01DOI: 10.1016/j.piel.2023.12.011
Sara Muñoz-Ordoñez, Jesús D. Fierro-Lozada, Laura Yiseth Calderón-Acero, Paola Andrea Russy-Buitrago, Neissen Nathaly Lozano-Reay, David A. Castillo-Molina
{"title":"Tratamiento del carcinoma basocelular localmente avanzado con vismodegib e itraconazol como coadyuvante","authors":"Sara Muñoz-Ordoñez, Jesús D. Fierro-Lozada, Laura Yiseth Calderón-Acero, Paola Andrea Russy-Buitrago, Neissen Nathaly Lozano-Reay, David A. Castillo-Molina","doi":"10.1016/j.piel.2023.12.011","DOIUrl":"10.1016/j.piel.2023.12.011","url":null,"abstract":"","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 6","pages":"Pages 377-379"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PielPub Date : 2024-05-22DOI: 10.1016/j.piel.2024.01.018
{"title":"No todo es efluvio telógeno. Alopecia areata difusa una entidad infradiagnosticada","authors":"","doi":"10.1016/j.piel.2024.01.018","DOIUrl":"10.1016/j.piel.2024.01.018","url":null,"abstract":"<div><div>The accurate differentiation between diffuse alopecia areata (DAA) and telogen effluvium (TE) is paramount in clinical dermatological practice due to the implications in therapeutic management and prognosis for the patient. Although both conditions might showcase similar clinical features, such as diffuse hair loss, their underlying etiologies and mechanisms are distinct. DAA is an autoimmune condition wherein the immune system targets the hair follicles, whereas TE is a temporary response to a physiological or stress-related shock, resulting in a synchronized telogen phase and subsequent hair shedding. Properly diagnosing and distinguishing these two conditions is not only crucial for setting an appropriate treatment course but also for guiding patients regarding long-term expectations. This article emphasizes the significance of correctly recognizing and differentiating DAA from TE, underlining the clinical impact of a misdiagnosis and the need for more efficient diagnostic tools in the dermatological field.</div></div>","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 8","pages":"Pages 495-502"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141140003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PielPub Date : 2024-05-10DOI: 10.1016/j.piel.2024.02.005
{"title":"Correlación dermatoscópica e histopatológica de la acropigmentación de Dohi","authors":"","doi":"10.1016/j.piel.2024.02.005","DOIUrl":"10.1016/j.piel.2024.02.005","url":null,"abstract":"","PeriodicalId":20182,"journal":{"name":"Piel","volume":"39 8","pages":"Pages 524-526"},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141037555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}